stockrow
Saturday 7 November 2026
Export LIMN’s income statement to Excel — free account
Liminatus Pharma Inc.
LIMN Healthcare Biotechnology
- EPS
- −717.0%
- Free cash flow
- +89.0%
- Total debt
- 0.00%
Quarter to June 2026, against a year earlier
2.50
0.13
−4.94%
Follow LIMN
Alert me
Liminatus Pharma Inc. (LIMN) P/E ratio
Liminatus Pharma Inc. has no meaningful P/E ratio: its trailing twelve-month earnings is negative. Over the past ten years it has ranged from 0.0× (November 2026) to 6.3× (March 2025) — the current reading is the lowest in ten years.
P/E ratio, daily
Embed this chart
Annual newest first
| Period | P/E ratio | Change |
|---|
Against its own ten years
Low 0.0×
High 6.3×
Ten-year median
0.0×
Current reading's percentile
98
P/E ratio against peers
| Company | P/E ratio |
|---|---|
| PBLA Panbela Therapeutics Inc. compare | n/m |
| CVKD Cadrenal Therapeutics, Inc. compare | n/m |
| DRMA Dermata Therapeutics, Inc. compare | n/m |
| LIMN Liminatus Pharma Inc. | n/m |
| ONCO Onconetix, Inc. compare | n/m |
| GRI GRI Bio, Inc. compare | n/m |
| LIPO Lipella Pharmaceuticals Inc. compare | n/m |
| TRAW Traws Pharma, Inc. compare | n/m |
| SXTP 60 Degrees Pharmaceuticals Inc. compare | n/m |
| Biotechnology industry median | 10.6× |
| Healthcare sector median | 24.5× |
| Market median | 17.8× |
What P/E ratio is
Price to Earnings Ratio shows how much investors pay for each dollar of a company’s annual profit per share.
Stock Price ÷ EPS (Basic) (TTM)